alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          11,914
<INT-BEARING-DEPOSITS>                           7,958
<FED-FUNDS-SOLD>                                    30
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     48,807
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                             6,119
<LOANS>                                        167,028
<ALLOWANCE>                                      2,251
<TOTAL-ASSETS>                                 260,044
<DEPOSITS>                                     223,414
<SHORT-TERM>                                    11,496
<LIABILITIES-OTHER>                              3,923
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         2,320
<OTHER-SE>                                      18,891
<TOTAL-LIABILITIES-AND-EQUITY>                 260,044
<INTEREST-LOAN>                                  3,973
<INTEREST-INVEST>                                  897
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                                 4,870
<INTEREST-DEPOSIT>                               1,762
<INTEREST-EXPENSE>                               2,037
<INTEREST-INCOME-NET>                            2,743
<LOAN-LOSSES>                                       90
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  4,011
<INCOME-PRETAX>                                    709
<INCOME-PRE-EXTRAORDINARY>                         709
<EXTRAORDINARY>                                    638
<CHANGES>                                            0
<NET-INCOME>                                     1,147
<EPS-BASIC>                                        .23
<EPS-DILUTED>                                      .23
<YIELD-ACTUAL>                                     .87
<LOANS-NON>                                      1,894
<LOANS-PAST>                                        11
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  1,772
<ALLOWANCE-OPEN>                                 1,612
<CHARGE-OFFS>                                    1,655
<RECOVERIES>                                       654
<ALLOWANCE-CLOSE>                                2,251
<ALLOWANCE-DOMESTIC>                             2,251
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
Biometric Technology Rally: 

Adapting to COVID-19 ·..;_' 

,~Homeland 

~ Security 

Sd enc-<- anrl Technology 

 

 

--- :_,_.. _;..:_ __ __ - ----

A 

.. 

BIOMETRIC AND IDENTITY TECHNOLOGY 

CENTER 

The Biometric and Identity Technology Center (BI-TC) 

serves as a resource for subject matter expertise in the 

science, methods, tools, and technologies used to 

recognize individuals and protect sensitive personal 

information. It enables Department of Homeland Security 

(DHS) components to cost-effectively maintain 

capabilities, enhance operations through effective use of 

new technologies, and inform strategic planning and 

acquisitions in developing new operational capabilities. 

BIOMETRIC TECHNOLOGY RALLY 

As commercially-available biometric technologies, such 

as collection devices and matching algorithms, continue 

to advance, the DHS Science and Technology 

Directorate (S&T) is driving biometric solutions and 

innovations within the Department. Through the BI-TC, 

S&T will conduct Biometric Technology Rallies with 

industry vendors to seek innovative solutions that will 

improve live biometric capture and matching. 

2020 RALLY DETAILS AND CHANGES 

Due to the COVID-19 pandemic, DHS priorities for the 

2020 Rally will focus on evaluating the ability of systems 

to reliably collect and/or match images of individuals, 

including individuals wearing face masks. The intent is to 

improve the ability to recognize people without requiring 

travelers to remove protective equipment, reducing risk 

for both the public and frontline DHS personnel. 

Originally, the evaluation also included processing small 

groups of up to 12 people, without disruption; however, 

this part of the evaluation will be deferred to 2021. 

The 2020 Biometric Technology Rally will take place in a 

laboratory test environment at S&T’s Maryland Test 

Facility (MdTF). It will evaluate vendors of both hardware 

and software through a standard, repeatable process. 

Can your system acquire/match face images 

from individuals wearing face masks? 

ADDITIONAL PROGRAM INFORMATION 

For more details about S&T’s Biometric Technology 

Rallies, visit https://www.dhs.gov/science-andtechnology/biometric-technology-rally. 

You can also watch an informational video on YouTube: 

https://www.youtube.com/watch?v=imv82Cuo2Pw. 

Contact Us: peoplescreening@hq.dhs.gov scitech.dhs.gov dhsscitech 07-2020
#### § 3700.437 What method do I use to communicate to a participant the requirements described in the OMB guidance at 2 CFR 180.435?

To communicate to a participant the requirements described in 2 CFR 180.435 of the OMB guidance, you as an agency official must include a term or condition in the transaction that requires the participant's compliance with subpart C of 2 CFR part 180, and requires the participant to include a similar term or condition in lower-tier covered transactions.
<PAGE>

EXHIBIT 32 (a)

      CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT
                TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Northland Cable Properties
      Seven Limited Partnership (the "Partnership") on Form 10Q for the period
      ended June 30, 2005 as filed with the Securities and Exchange Commission
      on the date hereof (the "Form 10-Q"), I, John Whetzell, Chief Executive
      Officer of Northland Communications Corporation, the General Partner,
      certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002, that;

            (1)   The Form 10-Q fully complies with the requirements of Section
                  13 (a) or (15(d) of the Securities Exchange Act of 1934 (15
                  U.S.C. 78m or 78(d)); and

            (2)   The information contained in the Form 10-Q fairly presents in
                  all material respects, the financial condition and results of
                  operations of the Partnership.

      DATE: 8-15-05

      /s/ JOHN S. WHETZELL
          -----------------------------------
          John S. Whetzell
          Chief Executive Officer

A signed original of this written statement required by Section 906 has been
provided to Northland Cable Properties Seven Limited Partnership and will be
retained by Northland Cable Properties Seven Limited Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.7 Promotion of investigational drugs. ( a ) *Promotion of an investigational new drug.* A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution.
( b ) *Commercial distribution of an investigational new drug.* A sponsor or investigator shall not commercially distribute or test market an investigational new drug.
( c ) *Prolonging an investigation.* A sponsor shall not unduly prolong an investigation after finding that the results of the investigation appear to establish sufficient data to support a marketing application.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 19476, May 22, 1987; 67 FR 9585, Mar. 4, 2002; 74 FR 40899, Aug. 13, 2009]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Securities and Exchange Commission

          - [File No. 500-1]

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Electronic Game Card, Inc. (“EGMI”) because of questions regarding the accuracy of assertions by EGMI, and by others, in financial disclosures to investors concerning, among other things, the company's assets.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

*Therefore, it is ordered,*                     pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EST, on February 19, 2010, through 11:59 p.m. EST, on March 4, 2010.                

By the Commission.

Jill M. Peterson,

Assistant Secretary.

[FR Doc. 2010-3643 Filed 2-19-10; 4:15 pm]

BILLING CODE 8011-01-P
**Exhibit 31.1**

 

CERTIFICATIONS

 

I, Carl Mostert, certify that:

 

1. I have reviewed thisquarterly report on Form 10-Q of Spescom Software, Inc.;

 

2. Based on my knowledge, thisquarterly report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;

 

3. Based on my knowledge, thefinancial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

 

4. The registrant’s othercertifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and15d-14) for the registrant and we have:

 

a) designed such disclosurecontrols and procedures, or caused such disclosure controls and procedures tobe designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which thisquarterly report is being prepared;

 

b) evaluated the effectivenessof the registrant’s disclosure controls and procedures and presented in thisquarterly report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this reportbased on such evaluation; and

 

c) disclosed in this report anychange in the registrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, the registrantsinternal control over financial reporting; and

 

5. The registrant’s othercertifying officers and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of registrant’s board of directors (or persons performingthe equivalent functions):

 

a) all significant deficienciesand material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financialinformation; and

 

b) any fraud, whether or notmaterial, that involves management or other employees who have a significantrole in the registrant’s internal control over financial reporting.

 

 
| Dated:   May 14, 2004 |
|----------------------------|
|                       |
| /s/ Carl  Mostert          |   |
| Carl Mostert               |
| Chief  Executive Officer   |

 

----
STATE OF LOUISIANA

VERSUS

KEVIN H. DUKES

A A

i 110 • 

NO. 2023 KW 1127

JANUARY 29, 2024

In Re: Kevin H. Dukes, applying for supervisory writs, 19th

Judicial District Court, Parish of East Baton Rouge, 

No. 01- 19- 0491. 

BEFORE: MCCLENDON, HESTER, AND MILLER, JJ. 

WRIT DENIED. Writ applications which consist of nothing

more than a list of claims without specific factual support

present nothing for this court to review. All assignments of

error and issues for review shall be briefed. The court may deem

as abandoned any issue for review which has not been briefed. 

See Uniform Rules of Louisiana Courts of Appeal, Rules 2- 

12. 4( B)( 4) & 4- 8. 

PMC

CHH

SHM

URT OF APPEAL, FIRST CIRCUIT

Y CLERK OF COURT

FOR THE COURT
[Federal Register Volume 75, Number 35 (Tuesday, February 23, 2010)]
[Notices]
[Page 8176]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3563]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice Number: 6372]


U.S. Advisory Commission on Public Diplomacy; Notice of Meeting

    The U.S. Advisory Commission on Public Diplomacy has rescheduled 
its public meeting to March 15, 2010 from 9 a.m. to 11 a.m. in the 
conference room of the International Foundation for Electoral Systems 
(IFES) located at 1850 K Street, NW., Fifth Floor, Washington, DC 
20006. This will replace the previously scheduled February 11 meeting 
(canceled due to inclement weather) at the same location.
    The Commissioners will discuss public diplomacy issues, including 
interagency collaboration in advancing U.S. government public diplomacy 
efforts.
    The Commission is a bipartisan panel created by Congress in 1948 to 
assess public diplomacy policies and programs of the U.S. government 
and of publicly funded nongovernmental organizations. The Commission 
reports its findings and recommendations to the President, the 
Congress, the Secretary of State, and the American people.
    The public may attend this meeting as seating capacity allows. To 
attend this meeting and for further information, please contact Carl 
Chan at (202) 632-2823; e-mail: <a href="/cdn-cgi/l/email-protection#d1b2b9b0bfb2ba91a2a5b0a5b4ffb6bea7"><span class="__cf_email__" data-cfemail="45262d242b262e0536312431206b222a33">[email protected]</span></a>. Any member of the 
public requesting reasonable accommodation at this meeting should 
contact Mr. Chan prior to March 8th. Requests received after that date 
will be considered, but might not be possible to fulfill.

    Dated: February 16, 2010.
Carl Chan,
Executive Director, ACPD.
[FR Doc. 2010-3563 Filed 2-22-10; 8:45 am]
BILLING CODE 4710-11-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1804 Sodium potassium tartrate. ( a ) Sodium potassium tartrate (C4H4KNaO6·4H2O, CAS Reg. No. 304-59-6) is the sodium potassium salt of l−(+)−tartaric acid and is also called the Rochelle salt. It occurs as colorless crystals or as a white, crystalline powder and has a cooling saline taste. It is obtained as a byproduct of wine manufacture.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 296, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an emulsifier as defined in § 170.3(o)(8) of this chapter and as a pH control agent as defined in § 170.3(o)(23) of this chapter.
( 2 ) The ingredient is used in the following foods at levels not to exceed current good manufacturing practice: cheeses as defined in § 170.3(n)(5) of this chapter and jams and jellies as defined in § 170.3(n)(28) of this chapter.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52447, Nov. 18, 1983]
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.73 Sodium polyacrylate. Sodium polyacrylate (CAS Reg. No. 9003-04-7) may be safely used in food in accordance with the following prescribed conditions: ( a ) The additive is produced by the polymerization of acrylic acid and subsequent hydrolysis of the polyacrylic acid with an aqueous sodium hydroxide solution. As determined by a method entitled “Determination of Weight Average and Number Average Molecular Weight of Sodium Polyacrylate,” which is incorporated by reference in accordance with 5 U.S.C. 552(a), the additive has— ( 1 ) A weight average molecular weight of 2,000 to 2,300; and
( 2 ) A weight average molecular weight to number average molecular weight ratio of not more than 1.3. Copies of the method are available from the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( b ) The additive is used to control mineral scale during the evaporation of beet sugar juice or cane sugar juice in the production of sugar in an amount not to exceed 3.6 parts per million by weight of the raw juice.
[53 FR 39456, Oct. 7, 1988; 53 FR 49823, Dec. 9, 1988, as amended at 88 FR 17722, Mar. 24, 2023]
**FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT**     FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (“Amendment”), dated September 21, 2006, by andamong Champion Retail, Inc., a Michigan corporation (“Seller”), Bayshore Advantage LLC, a Delawarelimited liability company (“Buyer”), and the other parties thereto.     The parties have entered into a Stock Purchase Agreement, dated September 8, 2006 (the“Purchase Agreement”), for the purchase by Buyer of the equity interests of San Jose AdvantageHomes, Inc., a California corporation. The parties wish to amend the Purchase Agreement asprovided herein.     NOW THEREFORE, in consideration of the mutual covenants herein contained, the parties agree asfollows:1. The first sentence of Section 2.1 of the Purchase Agreement is hereby amended to read in itsentirety as follows:“The closing of the transactions contemplated by this Agreement (the“Closing”) shall take place at the offices of Dykema Gossett PLLC, Suite300, 39577 Woodward, Bloomfield Hills, Michigan 48304, at 10:00 a.m., local time, onNovember 8, 2006, or at such earlier date as may be mutually agreed upon by Sellerand Buyer (such time and date being referred to herein as the “ClosingDate”).”2. This Amendment may be executed in one or more counterparts, each of which shall be deemed anoriginal, but all of which together shall constitute one and the same instrument.3. All other terms and conditions of the Purchase Agreement are hereby ratified and confirmed andremain in full force and effect.     IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first abovewritten.           BAYSHORE ADVANTAGE LLC   CHAMPION RETAIL, INC.             By: /s/ James D. Nichols   By: /s/ John J. Collins, Jr.             James D. Nichols, Managing Member   John J. Collins, Jr., Vice President             ENCORE PARTNERS, LLC   CHAMPION ENTERPRISES, INC.             By: /s/ James D. Nichols   By: /s/ John J. Collins, Jr.             James D. Nichols, Managing Member   John J. Collins, Jr., Senior Vice President  
****